ZD 6126

Drug Profile

ZD 6126

Alternative Names: ANG-453; ZD-6126

Latest Information Update: 07 Jul 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Angiogene Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Angiogenesis inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Suspended Solid tumours

Most Recent Events

  • 14 Feb 2005 A preclinical study has been added to the Cancer pharmacodynamics section
  • 03 Aug 2004 Preclinical studies in Solid tumours in the US - due to unexpected toxicity findings from phase II studies, ZD 6126 is now undergoing preclinical studies to explore scheduling options
  • 09 Oct 2003 Data presented at the 12th European Conference of Clinical Oncology (ECCO-2003) have been added to the pharmacokinetics and adverse events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top